Medical Care
Paroxysmal Nocturnal Hemoglobinuria Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Sep 11, 24
- ID: 546980
- Pages: 108
- Figures: 185
- Views: 2
The global market for Paroxysmal Nocturnal Hemoglobinuria Treatment was estimated to be worth US$ 3324.1 million in 2023 and is forecast to a readjusted size of US$ 5939.2 million by 2030 with a CAGR of 8.5% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Paroxysmal Nocturnal Hemoglobinuria Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Paroxysmal Nocturnal Hemoglobinuria Treatment by region & country, by Type, and by Application.
The Paroxysmal Nocturnal Hemoglobinuria Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Paroxysmal Nocturnal Hemoglobinuria Treatment.
Market Segmentation
By Company
Achillion Pharmaceuticals Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Apellis Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
ISU ABXIS Co Ltd
Novartis AG
NovelMed Therapeutics Inc
Omeros Corp
Ra Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Regenesance BV
Segment by Type:
ACH-4471
ALN-CC5
ALXN-1210
AMY-101
APL-2
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Paroxysmal Nocturnal Hemoglobinuria Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Paroxysmal Nocturnal Hemoglobinuria Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Paroxysmal Nocturnal Hemoglobinuria Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Paroxysmal Nocturnal Hemoglobinuria Treatment by region & country, by Type, and by Application.
The Paroxysmal Nocturnal Hemoglobinuria Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Paroxysmal Nocturnal Hemoglobinuria Treatment.
Market Segmentation
By Company
Achillion Pharmaceuticals Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Apellis Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
ISU ABXIS Co Ltd
Novartis AG
NovelMed Therapeutics Inc
Omeros Corp
Ra Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Regenesance BV
Segment by Type:
ACH-4471
ALN-CC5
ALXN-1210
AMY-101
APL-2
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Paroxysmal Nocturnal Hemoglobinuria Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Paroxysmal Nocturnal Hemoglobinuria Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Product Introduction
1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast
1.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Trends & Drivers
1.3.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Industry Trends
1.3.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers & Opportunity
1.3.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Challenges
1.3.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Players Revenue Ranking (2023)
2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Company (2019-2024)
2.3 Key Companies Paroxysmal Nocturnal Hemoglobinuria Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Paroxysmal Nocturnal Hemoglobinuria Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Paroxysmal Nocturnal Hemoglobinuria Treatment
2.6 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Competitive Analysis
2.6.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 ACH-4471
3.1.2 ALN-CC5
3.1.3 ALXN-1210
3.1.4 AMY-101
3.1.5 APL-2
3.1.6 Others
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type
3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application
4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region
5.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region (2019-2024)
5.1.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region (2025-2030)
5.1.4 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
5.2.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
5.3.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
5.5.2 South America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value
6.3 United States
6.3.1 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
6.3.2 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
6.4.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
6.5.2 China Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
6.6.2 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
6.7.2 South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
6.9.2 India Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Achillion Pharmaceuticals Inc
7.1.1 Achillion Pharmaceuticals Inc Profile
7.1.2 Achillion Pharmaceuticals Inc Main Business
7.1.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.1.4 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Achillion Pharmaceuticals Inc Recent Developments
7.2 Akari Therapeutics Plc
7.2.1 Akari Therapeutics Plc Profile
7.2.2 Akari Therapeutics Plc Main Business
7.2.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.2.4 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Akari Therapeutics Plc Recent Developments
7.3 Alexion Pharmaceuticals Inc
7.3.1 Alexion Pharmaceuticals Inc Profile
7.3.2 Alexion Pharmaceuticals Inc Main Business
7.3.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.3.4 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Alnylam Pharmaceuticals Inc Recent Developments
7.4 Alnylam Pharmaceuticals Inc
7.4.1 Alnylam Pharmaceuticals Inc Profile
7.4.2 Alnylam Pharmaceuticals Inc Main Business
7.4.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.4.4 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Alnylam Pharmaceuticals Inc Recent Developments
7.5 Amgen Inc
7.5.1 Amgen Inc Profile
7.5.2 Amgen Inc Main Business
7.5.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.5.4 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Amgen Inc Recent Developments
7.6 Apellis Pharmaceuticals Inc
7.6.1 Apellis Pharmaceuticals Inc Profile
7.6.2 Apellis Pharmaceuticals Inc Main Business
7.6.3 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.6.4 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Apellis Pharmaceuticals Inc Recent Developments
7.7 F. Hoffmann-La Roche Ltd
7.7.1 F. Hoffmann-La Roche Ltd Profile
7.7.2 F. Hoffmann-La Roche Ltd Main Business
7.7.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.7.4 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 F. Hoffmann-La Roche Ltd Recent Developments
7.8 ISU ABXIS Co Ltd
7.8.1 ISU ABXIS Co Ltd Profile
7.8.2 ISU ABXIS Co Ltd Main Business
7.8.3 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.8.4 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 ISU ABXIS Co Ltd Recent Developments
7.9 Novartis AG
7.9.1 Novartis AG Profile
7.9.2 Novartis AG Main Business
7.9.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.9.4 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 Novartis AG Recent Developments
7.10 NovelMed Therapeutics Inc
7.10.1 NovelMed Therapeutics Inc Profile
7.10.2 NovelMed Therapeutics Inc Main Business
7.10.3 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.10.4 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 NovelMed Therapeutics Inc Recent Developments
7.11 Omeros Corp
7.11.1 Omeros Corp Profile
7.11.2 Omeros Corp Main Business
7.11.3 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.11.4 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.11.5 Omeros Corp Recent Developments
7.12 Ra Pharmaceuticals Inc
7.12.1 Ra Pharmaceuticals Inc Profile
7.12.2 Ra Pharmaceuticals Inc Main Business
7.12.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.12.4 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.12.5 Ra Pharmaceuticals Inc Recent Developments
7.13 Regeneron Pharmaceuticals Inc
7.13.1 Regeneron Pharmaceuticals Inc Profile
7.13.2 Regeneron Pharmaceuticals Inc Main Business
7.13.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.13.4 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.13.5 Regeneron Pharmaceuticals Inc Recent Developments
7.14 Regenesance BV
7.14.1 Regenesance BV Profile
7.14.2 Regenesance BV Main Business
7.14.3 Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.14.4 Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.14.5 Regenesance BV Recent Developments
8 Industry Chain Analysis
8.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Industrial Chain
8.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Product Introduction
1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast
1.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Trends & Drivers
1.3.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Industry Trends
1.3.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers & Opportunity
1.3.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Challenges
1.3.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Players Revenue Ranking (2023)
2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Company (2019-2024)
2.3 Key Companies Paroxysmal Nocturnal Hemoglobinuria Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Paroxysmal Nocturnal Hemoglobinuria Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Paroxysmal Nocturnal Hemoglobinuria Treatment
2.6 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Competitive Analysis
2.6.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 ACH-4471
3.1.2 ALN-CC5
3.1.3 ALXN-1210
3.1.4 AMY-101
3.1.5 APL-2
3.1.6 Others
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type
3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application
4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region
5.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region (2019-2024)
5.1.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region (2025-2030)
5.1.4 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
5.2.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
5.3.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
5.5.2 South America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value
6.3 United States
6.3.1 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
6.3.2 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
6.4.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
6.5.2 China Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
6.6.2 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
6.7.2 South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019-2030
6.9.2 India Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Achillion Pharmaceuticals Inc
7.1.1 Achillion Pharmaceuticals Inc Profile
7.1.2 Achillion Pharmaceuticals Inc Main Business
7.1.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.1.4 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Achillion Pharmaceuticals Inc Recent Developments
7.2 Akari Therapeutics Plc
7.2.1 Akari Therapeutics Plc Profile
7.2.2 Akari Therapeutics Plc Main Business
7.2.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.2.4 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Akari Therapeutics Plc Recent Developments
7.3 Alexion Pharmaceuticals Inc
7.3.1 Alexion Pharmaceuticals Inc Profile
7.3.2 Alexion Pharmaceuticals Inc Main Business
7.3.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.3.4 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Alnylam Pharmaceuticals Inc Recent Developments
7.4 Alnylam Pharmaceuticals Inc
7.4.1 Alnylam Pharmaceuticals Inc Profile
7.4.2 Alnylam Pharmaceuticals Inc Main Business
7.4.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.4.4 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Alnylam Pharmaceuticals Inc Recent Developments
7.5 Amgen Inc
7.5.1 Amgen Inc Profile
7.5.2 Amgen Inc Main Business
7.5.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.5.4 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Amgen Inc Recent Developments
7.6 Apellis Pharmaceuticals Inc
7.6.1 Apellis Pharmaceuticals Inc Profile
7.6.2 Apellis Pharmaceuticals Inc Main Business
7.6.3 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.6.4 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Apellis Pharmaceuticals Inc Recent Developments
7.7 F. Hoffmann-La Roche Ltd
7.7.1 F. Hoffmann-La Roche Ltd Profile
7.7.2 F. Hoffmann-La Roche Ltd Main Business
7.7.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.7.4 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 F. Hoffmann-La Roche Ltd Recent Developments
7.8 ISU ABXIS Co Ltd
7.8.1 ISU ABXIS Co Ltd Profile
7.8.2 ISU ABXIS Co Ltd Main Business
7.8.3 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.8.4 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 ISU ABXIS Co Ltd Recent Developments
7.9 Novartis AG
7.9.1 Novartis AG Profile
7.9.2 Novartis AG Main Business
7.9.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.9.4 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 Novartis AG Recent Developments
7.10 NovelMed Therapeutics Inc
7.10.1 NovelMed Therapeutics Inc Profile
7.10.2 NovelMed Therapeutics Inc Main Business
7.10.3 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.10.4 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 NovelMed Therapeutics Inc Recent Developments
7.11 Omeros Corp
7.11.1 Omeros Corp Profile
7.11.2 Omeros Corp Main Business
7.11.3 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.11.4 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.11.5 Omeros Corp Recent Developments
7.12 Ra Pharmaceuticals Inc
7.12.1 Ra Pharmaceuticals Inc Profile
7.12.2 Ra Pharmaceuticals Inc Main Business
7.12.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.12.4 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.12.5 Ra Pharmaceuticals Inc Recent Developments
7.13 Regeneron Pharmaceuticals Inc
7.13.1 Regeneron Pharmaceuticals Inc Profile
7.13.2 Regeneron Pharmaceuticals Inc Main Business
7.13.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.13.4 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.13.5 Regeneron Pharmaceuticals Inc Recent Developments
7.14 Regenesance BV
7.14.1 Regenesance BV Profile
7.14.2 Regenesance BV Main Business
7.14.3 Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
7.14.4 Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (US$ Million) & (2019-2024)
7.14.5 Regenesance BV Recent Developments
8 Industry Chain Analysis
8.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Industrial Chain
8.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Trends
Table 2. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers & Opportunity
Table 3. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Challenges
Table 4. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints
Table 5. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Paroxysmal Nocturnal Hemoglobinuria Treatment Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Paroxysmal Nocturnal Hemoglobinuria Treatment Product Type
Table 9. Key Companies Time to Begin Mass Production of Paroxysmal Nocturnal Hemoglobinuria Treatment
Table 10. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region (2019-2024) & (%)
Table 27. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2025-2030) & (US$ Million)
Table 31. Achillion Pharmaceuticals Inc Basic Information List
Table 32. Achillion Pharmaceuticals Inc Description and Business Overview
Table 33. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 34. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Achillion Pharmaceuticals Inc (2019-2024)
Table 35. Achillion Pharmaceuticals Inc Recent Developments
Table 36. Akari Therapeutics Plc Basic Information List
Table 37. Akari Therapeutics Plc Description and Business Overview
Table 38. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 39. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Akari Therapeutics Plc (2019-2024)
Table 40. Akari Therapeutics Plc Recent Developments
Table 41. Alexion Pharmaceuticals Inc Basic Information List
Table 42. Alexion Pharmaceuticals Inc Description and Business Overview
Table 43. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 44. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Alexion Pharmaceuticals Inc (2019-2024)
Table 45. Alexion Pharmaceuticals Inc Recent Developments
Table 46. Alnylam Pharmaceuticals Inc Basic Information List
Table 47. Alnylam Pharmaceuticals Inc Description and Business Overview
Table 48. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 49. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Alnylam Pharmaceuticals Inc (2019-2024)
Table 50. Alnylam Pharmaceuticals Inc Recent Developments
Table 51. Amgen Inc Basic Information List
Table 52. Amgen Inc Description and Business Overview
Table 53. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 54. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Amgen Inc (2019-2024)
Table 55. Amgen Inc Recent Developments
Table 56. Apellis Pharmaceuticals Inc Basic Information List
Table 57. Apellis Pharmaceuticals Inc Description and Business Overview
Table 58. Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 59. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Apellis Pharmaceuticals Inc (2019-2024)
Table 60. Apellis Pharmaceuticals Inc Recent Developments
Table 61. F. Hoffmann-La Roche Ltd Basic Information List
Table 62. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 63. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 64. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of F. Hoffmann-La Roche Ltd (2019-2024)
Table 65. F. Hoffmann-La Roche Ltd Recent Developments
Table 66. ISU ABXIS Co Ltd Basic Information List
Table 67. ISU ABXIS Co Ltd Description and Business Overview
Table 68. ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 69. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of ISU ABXIS Co Ltd (2019-2024)
Table 70. ISU ABXIS Co Ltd Recent Developments
Table 71. Novartis AG Basic Information List
Table 72. Novartis AG Description and Business Overview
Table 73. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 74. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Novartis AG (2019-2024)
Table 75. Novartis AG Recent Developments
Table 76. NovelMed Therapeutics Inc Basic Information List
Table 77. NovelMed Therapeutics Inc Description and Business Overview
Table 78. NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 79. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of NovelMed Therapeutics Inc (2019-2024)
Table 80. NovelMed Therapeutics Inc Recent Developments
Table 81. Omeros Corp Basic Information List
Table 82. Omeros Corp Description and Business Overview
Table 83. Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 84. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Omeros Corp (2019-2024)
Table 85. Omeros Corp Recent Developments
Table 86. Ra Pharmaceuticals Inc Basic Information List
Table 87. Ra Pharmaceuticals Inc Description and Business Overview
Table 88. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 89. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Ra Pharmaceuticals Inc (2019-2024)
Table 90. Ra Pharmaceuticals Inc Recent Developments
Table 91. Regeneron Pharmaceuticals Inc Basic Information List
Table 92. Regeneron Pharmaceuticals Inc Description and Business Overview
Table 93. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 94. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Regeneron Pharmaceuticals Inc (2019-2024)
Table 95. Regeneron Pharmaceuticals Inc Recent Developments
Table 96. Regenesance BV Basic Information List
Table 97. Regenesance BV Description and Business Overview
Table 98. Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 99. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Regenesance BV (2019-2024)
Table 100. Regenesance BV Recent Developments
Table 101. Key Raw Materials Lists
Table 102. Raw Materials Key Suppliers Lists
Table 103. Paroxysmal Nocturnal Hemoglobinuria Treatment Downstream Customers
Table 104. Paroxysmal Nocturnal Hemoglobinuria Treatment Distributors List
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 108. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Paroxysmal Nocturnal Hemoglobinuria Treatment Product Picture
Figure 2. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value (2019-2030) & (US$ Million)
Figure 4. Paroxysmal Nocturnal Hemoglobinuria Treatment Report Years Considered
Figure 5. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2023
Figure 7. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. ACH-4471 Picture
Figure 9. ALN-CC5 Picture
Figure 10. ALXN-1210 Picture
Figure 11. AMY-101 Picture
Figure 12. APL-2 Picture
Figure 13. Others Picture
Figure 14. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value Market Share by Type, 2023 & 2030
Figure 16. Product Picture of Hospital
Figure 17. Product Picture of Clinic
Figure 18. Product Picture of Others
Figure 19. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 20. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value Market Share by Application, 2023 & 2030
Figure 21. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value (2019-2030) & (US$ Million)
Figure 22. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
Figure 23. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value (2019-2030) & (US$ Million)
Figure 24. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
Figure 25. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value (2019-2030) & (US$ Million)
Figure 26. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
Figure 27. South America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value (2019-2030) & (US$ Million)
Figure 28. South America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
Figure 29. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value (2019-2030) & (US$ Million)
Figure 30. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
Figure 31. Key Countries/Regions Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value (%), (2019-2030)
Figure 32. United States Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 33. United States Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
Figure 34. United States Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (%), 2023 VS 2030
Figure 35. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 36. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
Figure 37. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (%), 2023 VS 2030
Figure 38. China Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 39. China Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
Figure 40. China Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (%), 2023 VS 2030
Figure 41. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 42. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
Figure 43. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (%), 2023 VS 2030
Figure 44. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 45. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
Figure 46. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (%), 2023 VS 2030
Figure 47. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 48. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
Figure 49. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (%), 2023 VS 2030
Figure 50. India Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 51. India Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
Figure 52. India Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (%), 2023 VS 2030
Figure 53. Paroxysmal Nocturnal Hemoglobinuria Treatment Industrial Chain
Figure 54. Paroxysmal Nocturnal Hemoglobinuria Treatment Manufacturing Cost Structure
Figure 55. Channels of Distribution (Direct Sales, and Distribution)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Table 1. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Trends
Table 2. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers & Opportunity
Table 3. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Challenges
Table 4. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints
Table 5. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Paroxysmal Nocturnal Hemoglobinuria Treatment Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Paroxysmal Nocturnal Hemoglobinuria Treatment Product Type
Table 9. Key Companies Time to Begin Mass Production of Paroxysmal Nocturnal Hemoglobinuria Treatment
Table 10. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region (2019-2024) & (%)
Table 27. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2025-2030) & (US$ Million)
Table 31. Achillion Pharmaceuticals Inc Basic Information List
Table 32. Achillion Pharmaceuticals Inc Description and Business Overview
Table 33. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 34. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Achillion Pharmaceuticals Inc (2019-2024)
Table 35. Achillion Pharmaceuticals Inc Recent Developments
Table 36. Akari Therapeutics Plc Basic Information List
Table 37. Akari Therapeutics Plc Description and Business Overview
Table 38. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 39. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Akari Therapeutics Plc (2019-2024)
Table 40. Akari Therapeutics Plc Recent Developments
Table 41. Alexion Pharmaceuticals Inc Basic Information List
Table 42. Alexion Pharmaceuticals Inc Description and Business Overview
Table 43. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 44. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Alexion Pharmaceuticals Inc (2019-2024)
Table 45. Alexion Pharmaceuticals Inc Recent Developments
Table 46. Alnylam Pharmaceuticals Inc Basic Information List
Table 47. Alnylam Pharmaceuticals Inc Description and Business Overview
Table 48. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 49. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Alnylam Pharmaceuticals Inc (2019-2024)
Table 50. Alnylam Pharmaceuticals Inc Recent Developments
Table 51. Amgen Inc Basic Information List
Table 52. Amgen Inc Description and Business Overview
Table 53. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 54. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Amgen Inc (2019-2024)
Table 55. Amgen Inc Recent Developments
Table 56. Apellis Pharmaceuticals Inc Basic Information List
Table 57. Apellis Pharmaceuticals Inc Description and Business Overview
Table 58. Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 59. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Apellis Pharmaceuticals Inc (2019-2024)
Table 60. Apellis Pharmaceuticals Inc Recent Developments
Table 61. F. Hoffmann-La Roche Ltd Basic Information List
Table 62. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 63. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 64. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of F. Hoffmann-La Roche Ltd (2019-2024)
Table 65. F. Hoffmann-La Roche Ltd Recent Developments
Table 66. ISU ABXIS Co Ltd Basic Information List
Table 67. ISU ABXIS Co Ltd Description and Business Overview
Table 68. ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 69. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of ISU ABXIS Co Ltd (2019-2024)
Table 70. ISU ABXIS Co Ltd Recent Developments
Table 71. Novartis AG Basic Information List
Table 72. Novartis AG Description and Business Overview
Table 73. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 74. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Novartis AG (2019-2024)
Table 75. Novartis AG Recent Developments
Table 76. NovelMed Therapeutics Inc Basic Information List
Table 77. NovelMed Therapeutics Inc Description and Business Overview
Table 78. NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 79. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of NovelMed Therapeutics Inc (2019-2024)
Table 80. NovelMed Therapeutics Inc Recent Developments
Table 81. Omeros Corp Basic Information List
Table 82. Omeros Corp Description and Business Overview
Table 83. Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 84. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Omeros Corp (2019-2024)
Table 85. Omeros Corp Recent Developments
Table 86. Ra Pharmaceuticals Inc Basic Information List
Table 87. Ra Pharmaceuticals Inc Description and Business Overview
Table 88. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 89. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Ra Pharmaceuticals Inc (2019-2024)
Table 90. Ra Pharmaceuticals Inc Recent Developments
Table 91. Regeneron Pharmaceuticals Inc Basic Information List
Table 92. Regeneron Pharmaceuticals Inc Description and Business Overview
Table 93. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 94. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Regeneron Pharmaceuticals Inc (2019-2024)
Table 95. Regeneron Pharmaceuticals Inc Recent Developments
Table 96. Regenesance BV Basic Information List
Table 97. Regenesance BV Description and Business Overview
Table 98. Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Products, Services and Solutions
Table 99. Revenue (US$ Million) in Paroxysmal Nocturnal Hemoglobinuria Treatment Business of Regenesance BV (2019-2024)
Table 100. Regenesance BV Recent Developments
Table 101. Key Raw Materials Lists
Table 102. Raw Materials Key Suppliers Lists
Table 103. Paroxysmal Nocturnal Hemoglobinuria Treatment Downstream Customers
Table 104. Paroxysmal Nocturnal Hemoglobinuria Treatment Distributors List
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 108. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Paroxysmal Nocturnal Hemoglobinuria Treatment Product Picture
Figure 2. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value (2019-2030) & (US$ Million)
Figure 4. Paroxysmal Nocturnal Hemoglobinuria Treatment Report Years Considered
Figure 5. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2023
Figure 7. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. ACH-4471 Picture
Figure 9. ALN-CC5 Picture
Figure 10. ALXN-1210 Picture
Figure 11. AMY-101 Picture
Figure 12. APL-2 Picture
Figure 13. Others Picture
Figure 14. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value Market Share by Type, 2023 & 2030
Figure 16. Product Picture of Hospital
Figure 17. Product Picture of Clinic
Figure 18. Product Picture of Others
Figure 19. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 20. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value Market Share by Application, 2023 & 2030
Figure 21. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value (2019-2030) & (US$ Million)
Figure 22. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
Figure 23. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value (2019-2030) & (US$ Million)
Figure 24. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
Figure 25. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value (2019-2030) & (US$ Million)
Figure 26. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
Figure 27. South America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value (2019-2030) & (US$ Million)
Figure 28. South America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
Figure 29. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value (2019-2030) & (US$ Million)
Figure 30. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Country (%), 2023 VS 2030
Figure 31. Key Countries/Regions Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value (%), (2019-2030)
Figure 32. United States Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 33. United States Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
Figure 34. United States Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (%), 2023 VS 2030
Figure 35. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 36. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
Figure 37. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (%), 2023 VS 2030
Figure 38. China Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 39. China Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
Figure 40. China Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (%), 2023 VS 2030
Figure 41. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 42. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
Figure 43. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (%), 2023 VS 2030
Figure 44. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 45. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
Figure 46. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (%), 2023 VS 2030
Figure 47. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 48. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
Figure 49. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (%), 2023 VS 2030
Figure 50. India Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 51. India Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Type (%), 2023 VS 2030
Figure 52. India Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Value by Application (%), 2023 VS 2030
Figure 53. Paroxysmal Nocturnal Hemoglobinuria Treatment Industrial Chain
Figure 54. Paroxysmal Nocturnal Hemoglobinuria Treatment Manufacturing Cost Structure
Figure 55. Channels of Distribution (Direct Sales, and Distribution)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
DigitalBroadcast and Cinematography Cameras Lease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Mobile and Web Event Analytics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Business Information - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232